These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26497565)

  • 1. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.
    Broomfield A; Fletcher J; Davison J; Finnegan N; Fenton M; Chikermane A; Beesley C; Harvey K; Cullen E; Stewart C; Santra S; Vijay S; Champion M; Abulhoul L; Grunewald S; Chakrapani A; Cleary MA; Jones SA; Vellodi A
    J Inherit Metab Dis; 2016 Mar; 39(2):261-71. PubMed ID: 26497565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study.
    Tardieu M; Cudejko C; Cano A; Hoebeke C; Bernoux D; Goetz V; Pichard S; Brassier A; Schiff M; Feillet F; Rollier P; Mention K; Dobbelaere D; Fouilhoux A; Espil-Taris C; Eyer D; Huet F; Walther-Louvier U; Barth M; Chevret L; Kuster A; Lefranc J; Neveu J; Pitelet G; Ropars J; Rivier F; Roubertie A; Touati G; Vanhulle C; Tardieu E; Caillaud C; Froissart R; Champeaux M; Labarthe F; Chabrol B
    Eur J Neurol; 2023 Sep; 30(9):2828-2837. PubMed ID: 37235686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
    Banugaria SG; Prater SN; Patel TT; Dearmey SM; Milleson C; Sheets KB; Bali DS; Rehder CW; Raiman JA; Wang RA; Labarthe F; Charrow J; Harmatz P; Chakraborty P; Rosenberg AS; Kishnani PS
    PLoS One; 2013; 8(6):e67052. PubMed ID: 23825616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
    van Gelder CM; Poelman E; Plug I; Hoogeveen-Westerveld M; van der Beek NAME; Reuser AJJ; van der Ploeg AT
    J Inherit Metab Dis; 2016 May; 39(3):383-390. PubMed ID: 26768149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
    Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
    Berrier KL; Kazi ZB; Prater SN; Bali DS; Goldstein J; Stefanescu MC; Rehder CW; Botha EG; Ellaway C; Bhattacharya K; Tylki-Szymanska A; Karabul N; Rosenberg AS; Kishnani PS
    Genet Med; 2015 Nov; 17(11):912-8. PubMed ID: 25741864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction.
    Li C; Desai AK; Gupta P; Dempsey K; Bhambhani V; Hopkin RJ; Ficicioglu C; Tanpaiboon P; Craigen WJ; Rosenberg AS; Kishnani PS
    Genet Med; 2021 May; 23(5):845-855. PubMed ID: 33495531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
    Bali DS; Goldstein JL; Banugaria S; Dai J; Mackey J; Rehder C; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):40-9. PubMed ID: 22252923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series.
    ElMallah MK; Desai AK; Nading EB; DeArmey S; Kravitz RM; Kishnani PS
    Pediatr Pulmonol; 2020 Mar; 55(3):674-681. PubMed ID: 31899940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience.
    Chakrapani A; Vellodi A; Robinson P; Jones S; Wraith JE
    J Inherit Metab Dis; 2010 Dec; 33(6):747-50. PubMed ID: 20865334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.
    Banugaria SG; Prater SN; Ng YK; Kobori JA; Finkel RS; Ladda RL; Chen YT; Rosenberg AS; Kishnani PS
    Genet Med; 2011 Aug; 13(8):729-36. PubMed ID: 21637107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
    Desai AK; Kazi ZB; Bali DS; Kishnani PS
    Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.